Year: 2020

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the third quarter of 2020.“We are very pleased to reach the significant milestone of dosing the first patients in our Phase 2 clinical trial of KER-050. The initiation of this trial is a tremendous accomplishment for Keros and moves us closer to proof-of-concept by potentially demonstrating therapeutic benefit for patients with myelodysplastic syndromes (“MDS”),” said Jasbir S. Seehra, Ph.D., President and Chief...

MILWAUKEE, Nov. 10, 2020 (GLOBE NEWSWIRE) — Artisan Partners Asset Management Inc. (NYSE: APAM) today reported that its assets under management (“AUM”) as of October 31, 2020 totaled $131.5 billion. Separate accounts1 accounted for $69.6 billion of total firm AUM, while Artisan Funds and Artisan Global Funds accounted for $61.9 billion.1 Separate account AUM consists of the assets we manage in or through vehicles other than Artisan Funds or Artisan Global Funds. Separate account AUM includes assets we manage in traditional separate accounts, as well as assets we manage in Artisan-branded collective investment trusts, in funds (both public and private) that we sub-advise, and in our own privately offered funds.2 Effective October 1, 2020, the Artisan Partners Thematic Team was renamed the Antero Peak Group.3 Other Assets...

CONCORD, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — AssetMark Financial Holdings, Inc. (NYSE: AMK) released its “AssetMark Monthly Knowledge” Report today.Company highlights for the month of October 2020 include:Platform assets of $66.5 billion at the end of October, up 12.3%% year-over-year.Net flows were $396 million in the month of October, down 47.5% year-over-year.AssetMark Trust Company client cash was $2.47 billion, up 38.8% year-over-year.Number of households increased 14.0% year-over-year to 183,774 at the end of October.This monthly data is being provided on a supplemental basis and should not be taken as a substitute for the Company’s financial statements filed with the Securities and Exchange Commission as part of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. This monthly data is...

VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced it is partnering with TransLink, Vancouver Coastal Health, VGH & UBC Hospital Foundation, Coalition for Healthcare Acquired Infection Reduction (“CHAIR”), and the University of British Columbia to test antimicrobial copper coatings on high-touch transit surfaces on buses and SkyTrain in Vancouver, B.C.Copper alloy surfaces are naturally antimicrobial with self-sanitizing properties, with research showing that these surfaces eliminate up to 99.9% of harmful bacteria and viruses.This project is the first of its kind on a transit system in North America and the latest in Teck’s ongoing efforts to promote the use of antimicrobial copper surfaces in healthcare and public spaces...

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products.“We are thrilled to collaborate with GSK to implement our leading MRD test across their groundbreaking hematology portfolio as a measure of treatment response and patient outcomes,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “MRD is increasingly used as an endpoint in clinical trials, and clonoSEQ has emerged as the premier test to reliably and accurately measure MRD to help advance novel...

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2020.“Over the last quarter, we have demonstrated the unique capability of our platform to translate the immune response at scale into data that informs the development of best-in-class, differentiated diagnostic and therapeutic solutions,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “This pandemic has highlighted the key role of the immune response in our understanding of disease. COVID-19 is a prime example of the power of our platform to...

VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles, reported financial results for the third quarter ended September 30, 2020.Third Quarter and Recent Company HighlightsCommenced production and successfully delivered the first shipment of SOLO EVs into the U.S. In-line with the Company’s ongoing vehicle rollout strategy, these SOLO EVs will be used specifically for high ROI activities, including press events, marketing, retail distribution, test drives, corporate and advertising purposes as well as fleet demonstrations.Expanded the SOLO retail footprint into six (6) additional high-traffic, upscale shopping centers in EV-friendly cities, including San Diego, CA;...

UNIONDALE, N.Y., Nov. 10, 2020 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (the “Company”) (NYSE: ABR) announced today that it plans to make a public offering of 7,000,000 shares of its common stock. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock.The Company intends to use the net proceeds from the offering to make investments relating to its business and for general corporate purposes. The Company also intends to use a portion of the net proceeds from this offering to purchase an aggregate of 700,000 shares, or 805,000 shares if the underwriters exercise in full their option to purchase additional shares, of the Company’s common stock from its Chief Executive Officer, Arbor Commercial Mortgage, LLC and/or estate...

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or the “Company”) reported a net loss of $15.7 million, or $0.62 per diluted share, for the third quarter of 2020 compared to net income of $7.5 million, or $0.31 per diluted share, for the third quarter of 2019.Third Quarter 2020 HighlightsGross written premiums increased by 55.4% to $103.0 million compared to $66.2 million in the third quarter of 2019Net loss was $15.7 million, or $0.62 per diluted share, compared to net income of $7.5 million, or $0.31 per diluted share, in the third quarter of 2019Adjusted net income excluding catastrophe losses(1) was $13.7 million, compared to $9.6 million in the third quarter of 2019Total loss ratio of 97.7% compared to 8.8% in the third quarter of 2019Catastrophe loss ratio of 86.9%(1) compared...